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ABSTRACT 
Objective: Adult Onset Still's disease (AOSD) is a systemic inflammatory condition of unknown 
aetiology characterized by typical episodes of spiking fever, evanescent rash, arthralgia, 
leukocytosis and hyperferritinemia. Given the lack of data in Italian series, we promote a 
multicentric data collection to characterise the clinical phenotype of Italian patients with adult-
onset Still’s disease (AOSD).  
Methods: Data from two hundred and forty-five subjects diagnosed with AOSD were collected by 
15 centres between March and May 2013. The diagnosis was made following Yamaguchi’s criteria. 
Data regarding clinical manifestations, laboratory features, disease course, and treatments were 
reported and compared with those presented in other published series of different ethnicity. 
Results: The most frequent features were: arthritis (93%), pyrexia (92.6%), leukocytosis (89%), 
negative ANA (90.4%), and neutrophilia (82%). As compared to other North American, North 
European, Middle Eastern, and Far Eastern cohorts, Italian data show differences in clinical and 
laboratory findings. Regarding the treatments, in 21.9% of cases corticosteroids and traditional 
DMARDs have not been able to control the disease while biologics have been shown to be 
effective in 48 to 58 patients. 
Conclusion: This retrospective work summarizes the largest Italian multicentre series of AOSD 
patients and present clinical and laboratory features that appear to be influenced by the ethnicity 
of the affected subjects. 
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Adult-onset still’s disease, retrospective study, clinical presentation, laboratory findings, biologic 
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INTRODUCTION 
 
Adult-onset Still's disease (AOSD) is a rare complex autoinflammatory disorder of unknown 
aetiology. First described in children by George Still in 1896 [1], same symptoms were reported in 
1971 by Eric Bywaters in adult patients who did not fulfil criteria for classic rheumatoid arthritis 
[2]. Its incidence is approximately 0.16 per 100,000 persons in France [3], and it affects usually 
young adults (median age 36 years). 
The pathogenesis of AOSD is unknown, but genetic factors and various infectious agents have 
been considered as predisposing factors [4]. Genetically predisposed individuals would develop 
autoinflammatory reactions to environmental triggers, leading to neutrophil and macrophage 
activation, a hallmark of AOSD.  
Main features of AOSD include high spiking fever, arthralgia or arthritis, evanescent skin rash, sore 
throat, hepatosplenomegaly, leukocytosis with neutrophilia, elevated liver enzymes and ESR, and 
hyperferritinemia with decreased glycosylated ferritin (<20%). According to the clinical course of 
the disease, AOSD may be conventionally divided into three main patterns [5]: monocyclic pattern, 
characterized by systemic single episode completely resolving within months; intermittent or 
polycyclic pattern, associated with one or more disease flares and characterized by complete 
remissions lasting to a couple of years; chronic pattern, usually associated with polyarthritis. 
Diagnosis is difficult, delayed and usually based on classification criteria set, such as Yamaguchi's 
and Fautrel's criteria [5-6]. Due to the heightened clinical heterogeneity in AOSD, exclusion of 
other entities including infectious, neoplastic and autoimmune disorders should be ruled out 
before any diagnosis. 
The treatment of AOSD remains largely empirical, relying only on small retrospective case series 
[7]. Patients usually respond to nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, 
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disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, and polyvalent 
intravenous immunoglobulins (IVIg). Biologic agents are considered for treatment of 
corticosteroids- and DMARDs-refractory cases and represent major therapeutic advances. IL-1 
inhibition with Anakinra (IL-1 receptor antagonist), Canakinumab (anti-IL-1 monoclonal antibody) 
or Rilonacept (anti-IL-1 fusion protein)seem to be effective, well tolerated and steroid-sparing in 
systemic AOSD patients, whereas TNF-α blockers could be interesting in chronic polyarticular 
AOSD. Inhibition of IL-6 with tocilizumab is documented and seems effective in patients with 
active arthritis [8]. 
Most of the data on AOSD come from monocentric studies with limited number of cases.  
The Italian Society of Rheumatology study group on autoinflammatory diseases promoted a multi-
centric data collection of Italian AOSD cases aiming to develop a national registry. In this work we 
report the clinical manifestations, laboratory profile, patterns of disease course and therapy, 
collected by the different centres.  
 
PATIENTS AND METHODS 
 
Fifteen Italian University Hospital centres participated in this retrospective study and collected 
clinical and laboratory data together with disease and therapy information from AOSD patients. 
Data is referred to a cohort of patients recorded between March and May 2013. Diagnosis of 
AOSD was based on Yamaguchi diagnostic criteria [6], and required the presence of 5 major, minor 
or exclusion findings, of whom 2 or more must be major. Major Yamaguchi criteria include the 
presence of intermittent high spiking fever (≥ 39°C) lasting one week or longer, arthralgia lasting 
more than 2 weeks, characteristic rash and leukocytosis (white blood cell count ≥ 10,000/µl per 
mm3) with >80% granulocytes; whereas minor criteria are sore throat, lymphadenopathy and/or 
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splenomegaly, abnormal liver function tests and negative rheumatoid factor and ANA titre. The 
presence of infections, malignancies and other rheumatic diseases are exclusion conditions. 
Each centre has recorded patients data by using a standardised form, created specifically for 
collecting AOSD cases. Together with clinical characteristics, laboratory features are reported 
including blood cell count, coagulation parameters, serum(SF) ferritin, ESR, C-reactive protein 
(CRP), liver enzymes, rheumatoid factor (RF), antinuclear autoantibody (ANA). 
All treatments were listed with information about doses, durations and adverse events, along with 
the follow-up of different biologic treatments.  
Concerning the disease course, the patients were stratified into four classes: polycyclic systemic, 
chronic articular polycyclic, monocyclic systemic, and chronic articular monocyclic. 
The collected data were compared with those reported in five published series of different ethnic 
origin and with samples size more than 50 subjects [4, 5, 8-10]. Descriptive statistics are 
represented as mean ± standard deviation (SD). 
This retrospective study was approved by Padua Hospital Ethics Committee. 
 
 
RESULTS 
 
Clinical features 
Two hundred and forty-five patients (116 females and 129 males) with AOSD diagnosis and 
Caucasian origin were collected. The median age at the onset of disease manifestations was 38.8 
years (range, 16-78.6), and the median delay of diagnosis was 1.5 months (range, 0-232). The 
disease manifestations were reported and compared with other series [4, 5, 8-10] in Table 1. At 
the time of onset, principal manifestations consisted on arthralgia (93%), arthritis (75.8%), pyrexia 
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(92.6%) and leucocytosis (89%). Patients experiencing fever report high temperature (39.1°C ± 0.7) 
and one or two spikes per day in 27.3% and 51.9% of cases, respectively. The pattern of fever was 
intermittent, with an average duration of 10.3 days and an intercritical phase of 3.2 days. Other 
symptoms observed in AOSD patients were: typical rash (67.7%), sore throat or pharyngitis 
(61.8%) and lymphoadenopathy (60.4%). Among patients with arthritis 23.7% had monoarthritis, 
44.3% had oligoarthritis and 32.0% had polyarthritis. 
Reactive hemophagocytic syndrome (RHS) was reported in 7 patients (2.85%). 
The clinical course in our patients were polycyclic systemic in 40.8% of cases, chronic 
articularpolycyclic in 30.7%, monocyclicsystemic in 23.9% and chronic articular monocyclic in 4.6%. 
 
Laboratory features 
As presented in Table 2, leukocytosis (white blood cell count ≥ 10,000/mm3) occurs in 81% of 
patients (mean ± SD, 16,200 ± 7,850/mm3) and was composed of ≥80% PMN in 70.3% (mean ± SD, 
13,483 ± 7,341/mm3). CRP was increased in 93% of patients (mean ± SD, 101.9 ± 88.6 mg/L) in a 
range 1-355mg/L. Platelet count was 378 ± 176 x109/L (range, 20-922) and thrombocytosis (>400 
x109/L) occurred in 46% of patients. 
Elevation of hepatic enzymes was observed in 53.5% of patients and rheumatoid factor was 
positive only in 3.8%. Patients were tested for autoantibodies: 0.5% of patients was positive for 
anti-CCP, 9.6% for ANA and 3.7% for anti-ENA. Serum ferritin above the normal levels was 
observed in 56.4% of patients (mean ± SD, 5,743 ± 9,723) within a range of 156-52,395). 
 
Comorbidities 
At the time of the last follow-up, almost 70% of patients presented comorbidities: cardiovascular 
diseases in 61 patients, pneumopathies in 17, nephritis in 12, hepatitis in 11,bowel diseases in 
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8,tyroiditis in 26, autoimmune diseases in 8, diabetes in 19,neoplasia in 6, and other diseases in 4 
patients(Table 3). 
 
Treatment 
84.5% of patients received steroids and 3% steroids in bolus. 51% of those patients took DMARDs 
and about 35% concomitant drugs (FANS), such as indomethacin, ibuprofen, diclofenac. Among 
patients treated with DMARDs, 60% used methotrexate, 18.5% cyclosporin, 13.2% 
hydroxychloroquine, 3.4% salazopyrin, 2.4% azathiopyrin and 2.4% leflunomide. 
As reported in Table 4, treatment with first line biologic agents was prescribed on 58 occasions 
(23.7%), 3.5 ± 4.3 years after the disease diagnosis and at 40.6 ± 15.3 years of age. Within them, 
46.6% received TNF-blockers and 53.4% Anakinra. Second line biologic drugs were used 19 times 
(7.7%), of which TNF-blockers in 10 patients, Anakinra in 4 patients and others in 5 patients. 
Moreover, third line biologic agents were used as treatment on 7 occasions (2.8%): 4 times TNF-
blockers and 3 times others. 
Forty-two patients are reported to continue with biologic treatments; in details, 30 patients use 
first line biologic agents (13 TNF-blockers and 17 Anakinra), 9 patients take second line agents (3 
TNF- blockers, 4 Anakinra, and 2 others), and 3 patients receive third line biologics (2 TNF-blockers 
and 1 others). Sixteen up to 58 patients treated with biologic agents have definitively withdrawn 
this treatment, due to adverse events (8 times), loss or lack of efficacy (2 times), and remission (6 
times). 
Given the absence of consensus regarding a disease activity measures in AOSD, the therapeutic 
efficacy of the biologic agents was evaluated based on disappearance of all clinical symptoms and 
biological manifestations (complete response, partial response, no response). The therapeutic 
efficacy of Anakinra and TNF-blockers is reported in Table 5. 
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DISCUSSION 
 
AOSD is a heterogeneous complex disorder with unknown pathogenesis and difficult diagnosis [7]. 
Due to the limited number of clinical cases, often referring to individual centers, the Italian Society 
of Rheumatology study group on autoinflammatory diseases promoted a multicentric collection of 
Italian AOSD patients data. The main aims of this registry are to define the clinical and laboratory 
pattern of AOSD and the therapeutic attitude towards the disease in Italy. Furthermore, as long-
term purpose, the registry aims to identify prognostic factors of the disease. Up to date, AOSD 
data on the Italian population derive only from monocentric studies and are not a complete 
representation of the nation [11-14]. 
In this retrospective study, we reported 245 patients with AOSD diagnosis referring to 15 Italian 
Rheumatologic Centres, 6 from northern Italy, 5 from central Italy and 4 from the southern Italy.To 
the best of our knowledge, this registry collects the largest number of AOSD patient data in Italy. 
Table 1 and 2 present a wide variability in the frequencies of clinical and laboratory features in our 
Italian AOSD patients compared with data from different ethnicity. Italian and Japanese patients 
were generally older at disease onset than subjects from the other series. In our study, the mean 
age of the patients at the time of diagnosis was 40.5 ± 16.5 years, whereas in other European 
countries, Turkey and China the mean age is around 34 years. The delay to final diagnosis was 
highly variable from 0 to 232 months (median 1.5 months), which indicates possible diagnostic 
difficulties. 
The tendency for AOSD to show female predominance has been already noticed [4, 5, 9, 10], but 
the reason is not clear. Curiously, in our population males and females are equally affected, this 
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may be due to an unexpected selection bias or may reflect a peculiar characteristic of the Italian 
population. 
In the present study, arthralgia (93%) and fever (92.6%) were the most common clinical findings, 
the frequency of which were similar to the other reported cases. Symptoms such as pharyngitis 
and maculopapular rash appear to be less frequent in Italian and Turkish subjects, whereas 
lymphadenopathy is most experienced by Italian, Spanish and Chinese patients than other series. 
Spanish patients showed the lowest frequency of hepatomegaly and sore throat, while the French 
subjects had the highest frequency of pericarditis. Recently, in a single-center retrospective study 
on 39 AOSD patients F. Dall'Ara et al. looked for predictors of the use of biologic agents. They 
suggested that pericarditis may be a possible marker of severe AOSD associated with higher 
probability of a disease refractory to conventional DMARDs. They found pericarditis in 7 patients 
(38%) receiving biologic agents and in 1 patient (5%) of those receiving traditional DMARDs. Our 
data show a similar tendency since we found pericarditis in 20% of patients receiving biologic 
agents and in 12% of patients receiving traditional DMARDs, thus supporting the suggestion that 
pericarditis in AOSD patients should be considered a red flag for clinicians. [15] 
In the Chinese cohort a higher prevalence of lymphadenopathy, hepatomegaly, maculopapular 
rash and pharyngitis was noted. In our series, rash, lymphadenopathy, and sore throat were 
sensitive (>60%) and specific (> 60%), suggesting that these 3 features are useful for establishing a 
diagnosis of AOSD in the Italian cohort. 
Hemophagocytic syndrome is a rare life-threatening syndrome that can complicate the course of 
AOSD. It is suggested that prevalence of RHS in AOSD is underestimated due to underdiagnosis in 
several cases. In our cohort, we observed RHS only in 2.8% of patients. This number is low in 
comparison to other AOSD series however is consistent with the recently reported results of 
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Zhang Y. et al. who retrospectively identified 10 cases of RHS among 315 AOSD patients (3.2%) 
[16]. 
With regard to clinical course, monocyclic subset was reported most commonly [14, 17], whereas 
in our cohort, most frequent subsets were polycyclic systemic pattern (40.8%) and chronic 
articular polyciclic (30.7%). 
Particular attention should be paid to the laboratory values, since it may be a very helpful 
diagnostic hint for AOSD. Among other laboratory features, the white blood cell count seems to be 
an interesting predictor of patient outcome. Increased white blood cell counts were associated 
with AOSD relapses, whereas other studies showed a significant association between elevated 
serum ESR or CRP and a poor prognoses or higher relapse rates [9,18]. 
Notably, the Italian cases experienced hyperferritinemia and showed a remarkably higher levels of 
serum ferritin respect to Turkey and Chinese series. Besides total ferritin level, the diagnostic 
interest of the glycosylated ferritin (GF) has been suggested [19]. Unfortunately GF determination 
was not available in Italian routine clinical practice at the time of the study enrollment. 
The determination of RF and ANA is also recommended, since it can be effective in narrowing the 
differential diagnosis. The frequency of RF and ANA positivity, always at low titre in our patients, is 
comparable to other studies. 
The treatment of AOSD remains largely empirical, based on few case studies but not on 
randomized trials. NSAIDs are traditionally recommended as initial treatment of AOSD, although 
they are rarely effective in controlling the disease with a response rate of 20-25% [20]. 
Corticosteroids are usually required to induce symptom remission and is indicated in case of life-
threatening complications in AOSD [21,22]. To reduce the effects of the steroids, 
immunomodulatory agents as methotrexate (MTX) can be used as second-line treatment [23]. 
However, if conventional immunosuppressive therapy is not effective, biological agents targeting 
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IL-1, IL-6 and TNF- represent major therapeutic advances. In our cases, corticosteroids and 
traditional DMARDs have not been able to control the disease in 21.9% of patients while biologics 
have been shown positive effects. The efficacy of infliximab (anti TNF-) in corticosteroid- and 
MTX-resistant AOSD patients was demonstrated in several case series and case reports [24,25]. 
Infliximab is generally well tolerated; however, it has been associated with side effects including 
infusion reactions, skin rash, infections, fulminant hepatitis and exacerbation of heart failure. 
Switching from one TNF-α inhibitor to another may be useful. In fact, Etanercept (anti TNF-α) was 
used successfully for the treatment of AOSD patients with complications, whereas adalimumab 
was effective as second line biologic drug in Etanercept or Infliximab not responders [26]. 
Treatment with IL-1 inhibitor (Anakinra) resulted in rapid and complete resolution of both 
systemic and articular manifestations as well as normalization of inflammatory marker levels [27]. 
Three of our cases received anti-IL-6 receptor, which has been considered for treating AOSD. A 
recent review of 35 patients reported that 86% of tocilizumab-treated patients experienced 
prompt articular improvement, and 96% experienced a disappearance of systemic symptoms [28]. 
We conducted a nationwide survey of AOSD, which provides important information on the clinical, 
laboratory, and therapeutic features in the greatest cohort of Italian patients. Nevertheless, the 
present study has few limitations. First, the study was retrospective and had to contend with some 
degree of missing clinical and laboratory investigation data. Therefore, we await additional studies 
from other institutions in different countries to enrich and confirm the present results. 
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  our data 
Fautrel 
2002 
Cagatay 
2009 
Kong 
2010 
Gerfaud-
Valentin 
2014 
Asanuma 
2014 
Average 
(731 patients) 
Country Italy France Turkey China Spain Japan 
 N. 245 72 84 104 57 169 
 Female 47.30% NR 70.20% 75% 53% 72% 55% 
Male 52.70% NR 29.80% 25% 47% 28% 35% 
a
Ageatonset 38.8 NR NR NR NR 46 42.4 
b
Delay of diagnosis 1.5 NR NR NR 4 1.5 2.33 
Arthralgia 93.00% 88.80% 96.40% 90% 95% 83.10% 90% 
Fever 92.60% 85% 95.20% 100% 95% 91.60% 93% 
Sore throat 62% NR 65.50% 78% 53% 59.30% 57% 
Maculo 
papularrash 67.70% 71% 59.50% 95% 77% 62.20% 70% 
Hepatomegaly 41.7% NR 38.10% 44% 21% NR 26% 
Lymphadenopathy/ 
Splenomegaly 60.40% 44.40% 33.30% 66% 60% 44.70% 53% 
Pericarditis 17.3% 20.80% 11.90% NR 19% 3.10% 11% 
 
Table. 1: Clinical manifestations of 245 Italian AOSD patients compared to 5 previously published 
series.The final column lists the average percentages of all patient series.  
NR= not reported.
a
= years (median). 
b
= months (median) 
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our data 
Fautrel 
2002 
Cagatay 
2009 
Kong 2010 
Gerfaud-
Valentin 
2014 
Asanuma 
2014 
Average 
(731 patients) 
CRP [mg/L] 
101.9 ± 
88.6 
NR 
115.9 ± 
68.1 
NR 
183.4 ± 
108.5 
positive in 
91.5% 
134 
elevated ESR 87% NR 94% 96% 96% 68.90%  
(>20 mm/h) 77% 
Leucocyte 
count 
16,200  ± 
7,854 
NR 
16,234 ± 
7,785 
NR 
13,930 ± 
7,050 
NR 15,455 
[N./mm3] 
> 
10.000/mm3 
81% 88.80% 84.15% 99% 72% 79.40% 84% 
Neutrophil 
count 
13,483 ± 
7,341 
NR NR 
>8,000 in 
98% 
11,980 ± 
6,140 
NR 12,732 
(N./mm3) 
PMN >80% 70.30% 69.80% 55.56% NR 77% 71.50% 59% 
Platelet 
count 378 ± 176 NR 378 ± 158 
> 300  in 
77% 
NR 
<15 in 
13.6% 
 
(109/L)  
>40.000/mm3 
46% NR 23.80% 26% 26% NR 24% 
Serum 
ferritin 
[ng/mL] 
5,743 ± 
9,723 
NR 
1,126 ± 
1,474 
NR 
8,745 [84-
130,000] 
NR 5,204 
>N 56.40% 69.40% NR 99% NR 88.50% 60% 
>3N  80.10% *38.9% *38% 83% NR 60% 53% 
Elevated liver 
enzymes 
53.50% 73.60% NR 62% 54% 73.90% 55% 
Negative 
ANA 
90.40% 91.70% NR 100% 92% 74.20% 78% 
Negative RF 96.20% 98.60% NR 95% 100% 79.90% 82% 
Table. 2:Laboratory features of 245 Italian AOSD patients compared to 5 previously published 
series.The final column lists the average values of all patient series. 
* = serum ferritin >5N 
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Comorbidities N. 
Autoimmune diseases   
Anti-CCP positivity 1 
Urticarial vasculitis 1 
Behçet disease 1 
Raynaud's syndrome 2 
Systemic lupus erithematosus 1 
Psoriasis 1 
IBD 1 
Neoplasia   
Prostatic carcinoma 2 
Frontal meningioma 2 
Chronic myeloproliferative disease 1 
Astrocytome 1 
 
Table. 3: Comorbidities in 245 Italian AOSD patients at the time of last follow-up. 
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Biologic Agents N. beginners (%) N. in progress (%) 
1st line biologics 
Anakinra 31 (53.4%) 17 (56.7%) 
TNF-blockers 27 (46.6%) 13 (43.3%) 
-Adalimumab 4 (6.9%)  
-Etanercept 12 (20.7%)  
-Infliximab 5 (8.6%)  
Total 58 (23.7%) 30 (12.2%) 
2nd line biologics 
Anakinra 4 (21.1%) 4 (44.4%) 
TNF-blockers 10 (52.6%) 3 (33.3%) 
-Adalimumab 5 (26.3%)  
-Etanercept 3 (15.8%)  
-Infliximab 2 (10.5%)  
Others 5 (26.3%) 2 (22.2%) 
-Abatacept 1 (5.3%)  
-Rituximab 2 (10.5%)  
-Tocilizumab 2 (10.5%)  
Total 19 (7.7%) 9 (3.7%) 
3rd line biologics 
Anakinra 0 (0%)  
TNF-blockers 4 (57.1%) 2 (66.7%) 
-Etanercept 2 (28.6%)  
-Golimumab 1 (14.3%)  
-Infliximab 1 (14.3%)  
Others 3 (42.9%) 1 (33.3%) 
-Abatacept 1 (14.3%)  
-Rituximab 1 (14.3%)  
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-Tocilizumab 1 (14.3%)  
Total 7 (2.8%) 3 (1.2%) 
 
Table. 4: First, second and third line of biologic treatments followed by Italian AOSD cohort.  
21 
 
 
 
Table 5: Therapeutic response to Anakinra and TNF-blockers in 76 treatment courses. 
*A patient cannot be evaluated, due to the short period of treatment. 
 Anakinra TNF-blockers 
complete response 26 9 
partial response 7 10 
no response 1 22 
Total treated 35* 41 
